Allakos (NASDAQ: ALLK) today released data from ENIGMA 2, a 24-week randomized, double-blind, placebo-controlled phase 3 study of lirentelimab in patients with biopsy-confirmed...
ByCAMEROON MAGAZINE - GM22/12/2021Le cours de l’action Allakos Inc (NASDAQ : ALLK) – une société de biotechnologie développant le lirentelimab (AK002) pour le traitement des maladies...
ByCAMEROON MAGAZINE - GM22/12/2021Allakos (ALLK) announces data from ENIGMA 2, a 24-week phase 3 study of lirentelimab in patients with biopsy-confirmed eosinophilic gastritis and / or...
ByCAMEROON MAGAZINE - GM22/12/2021